Form 4: ImmunityBio Director Cheryl Cohen Receives Significant Stock Option Grant

ImmunityBio, Inc. Director Cheryl Cohen was granted 162,786 stock options with an exercise price of $2.84, aligning her interests with shareholder value.

Summary

• Cheryl Cohen, a Director at ImmunityBio, Inc. (IBRX), was granted 162,786 stock options.
• The options have an exercise price of $2.84 per share.
• The grant date for these options was June 18, 2025.
• The options expire on June 18, 2035.
• The shares subject to the award will vest 100% on the earlier of June 18, 2026, or the date immediately preceding the Issuer's next annual meeting of stockholders.
• Vesting is contingent upon Ms. Cohen's continued service as a Service Provider under the Issuer's 2025 Equity Incentive Plan.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally viewed positively as it aligns the director's interests with the long-term success of the company and shareholder value. It indicates a commitment to retaining key personnel and incentivizing performance.

Positives

• The grant of stock options to a director aligns their financial interests with the long-term performance of the company and shareholder value.
• The options are granted under the Issuer's 2025 Equity Incentive Plan, indicating a structured approach to executive compensation.

Risks

• The vesting of the stock options is subject to the reporting person's continuing to be a Service Provider, meaning the options could be forfeited if service ceases before vesting.

Future Outlook

The stock options are set to vest 100% on the earlier of June 18, 2026, or the date immediately preceding the Issuer's next annual meeting of stockholders, contingent on continued service.

Industry Context

The grant of stock options is a common form of executive and director compensation in the biotechnology and pharmaceutical industries, designed to incentivize long-term performance and align leadership interests with shareholder returns. This practice is standard across publicly traded companies, particularly in sectors requiring significant long-term R&D investment.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value, potentially leading to more focused long-term decision-making.

Next Steps

• Vesting of the 162,786 stock options on the earlier of June 18, 2026, or the date immediately preceding the Issuer's next annual meeting of stockholders.
• Potential exercise of vested stock options by Cheryl Cohen before the expiration date of June 18, 2035.

Key Dates

Keywords

ImmunityBio, IBRX, Cheryl Cohen, Stock Options, SEC Form 4, Insider Transaction, Director Compensation, Equity Incentive Plan, Biotechnology, Pharmaceuticals